Secarna Pharmaceuticals to Showcase ASO Potential at Inflammasome Therapeutics Summit

Secarna Pharmaceuticals will present conclusive data at the 6th Inflammasome Therapeutics Summit, highlighting the potential of their third-generation antisense oligonucleotides (ASOs) to target NLRP3 expression. NLRP3 is a key component in the inflammation process linked to various diseases.

Research in collaboration with experts from the University of California San Diego demonstrated that ASOs can effectively suppress NLRP3 and IL-1β, extending survival and reducing systemic inflammation in a CAPS mouse model. These findings suggest ASO therapy could offer new treatment options for CAPS and other NLRP3-mediated diseases.

The summit will be held in Boston from September 10-12, 2024. Julia Hinterdobler, PhD, will present the talk on September 11th, showcasing the successful use of Secarna's AI-powered bioinformatics to design these effective ASOs.